IP Library Granted Patent US 8,865,769
Granted Patent B2
US 8,865,769 · App. 13/691,981 · Granted Oct 21, 2014

Baclofen and acamprosate based therapy of neurological disorders

Inventors: Daniel Cohen (Le Vesinet, FR); Ilya Chumakov (Vaux le Penil, FR); Serguei Nabirochkin (Chatenay Malabry, FR); Emmanuel Vial (Paris, FR); Mickael Guedj (Paris, FR)
Assignee: Pharnext
A61K31/197A61K31/445A61K31/42A61K31/44A61K31/195A61K31/185A61K31/138A61K31/164A61K45/06A61K31/137A61K31/64A61K31/145
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,865,769
App. No.
13/691,981
Granted
Oct 21, 2014
Kind
B2
Abstract

The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.

Claims (10)

1. A composition comprising a synergistic combination of baclofen and acamprosate or pharmaceutically acceptable salts thereof.

2. The composition of claim 1 , said composition further comprising donepezil.

3. The composition of claim 1 , wherein the compounds are mixed with a pharmaceutically acceptable carrier or excipient.

4. The composition of claim 1 , wherein the ratio acamprosate/baclofen (W:W) is between 0.1 and 1000.

5. The composition of claim 1 , which comprises a unit dose of baclofen of less than 100 mg.

6. The composition of claim 1 , which comprises a unit dose of acamprosate of less than 400 mg.

7. The composition of claim 1 , which comprises a calcium salt of acamprosate.

8. The composition of claim 1 , which comprises baclofen and acamprosate as the only active agents.

9. A composition comprising synergistically effective amounts of baclofen and acamprosate or pharmaceutically acceptable salts thereof, mixed with a pharmaceutically acceptable carrier or excipient, acamprosate being at a unit-dose of less than 400 mg.

10. A composition comprising, mixed in a unit-dose with a pharmaceutically acceptable carrier or excipient, baclofen or a pharmaceutically acceptable salt thereof in a unit-dose of less than 100 mg and acamprosate or a pharmaceutically acceptable salt thereof in a unit-dose of less than 400 mg, wherein the unit-doses of baclofen and acamprosate are provided in synergistically effective amounts.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 13, 2022
From: IPF MANAGEMENT S.A., AS BONDHOLDERS' REPRESENTATIVE
To: PHARNEXT S.A.
Reel/Frame 061081/0098 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2018
From: KREOS CAPITAL IV (UK) LIMITED
To: PHARNEXT
Reel/Frame 046895/0584 →
SECURITY INTEREST Recorded Sep 4, 2018
From: PHARNEXT S.A.
To: IPF MANAGEMENT S.A., AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 046775/0111 →
SECURITY INTEREST Recorded Apr 12, 2016
From: PHARNEXT
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 038251/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2012
From: COHEN, DANIEL; CHUMAKOV, ILYA; NABIROCHKIN, SERGUEI; VIAL, EMMANUEL; GUEDJ, MICKAEL
To: PHARNEXT
Reel/Frame 029391/0277 →
Priority Claims (2)
EP 11305217 · Mar 1, 2011 · regional
EP 11305687 · Jun 6, 2011 · regional
Continuity (4)
Continuation PCTEP2012053570 · Mar 1, 2012
Provisional Application 61468658 · Mar 29, 2011
Provisional Application 61493606 · Jun 6, 2011
Related Publication 20130085122A1 · Apr 4, 2013